GTx Announces Panel Discussion at Citi’s 6th Annual Biotech Day

MEMPHIS, Tenn.--(BUSINESS WIRE)-- GTx, Inc. (NASDAQ: GTXI) announced today that Dr. Mitchell S. Steiner, CEO, is scheduled to participate in a panel discussion on the topic “Finally, Lots of Options for Treating Prostate Cancer ” at Citi’s 6th Annual Biotech Day on Wednesday, September 7, 2011, at 11:00 a.m. ET. The conference will be held at the Ritz Carlton hotel in Boston, Massachusetts.

About GTx

GTx, Inc., headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules that selectively target hormone pathways for the treatment of cancer, cancer supportive care, and other serious medical conditions.


GTx, Inc.
McDavid Stilwell, 901-523-9700
Director, Corporate Communications & Financial Analysis

KEYWORDS:   United States  North America  Massachusetts  Tennessee

INDUSTRY KEYWORDS:   Health  Biotechnology  Consumer  General Health  Men



Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.